In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Welsh Carson Sits in K2M Driver's Seat

Executive Summary

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.
Advertisement

Related Content

Device M&A Poised For A Strong Year
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
Welsh Carson Taps Into Spinal Market with K2M Buy
Despite Surgeon Support, NEJM Vertebroplasty Articles Spark Slowdown, Reimbursement Review
Despite Surgeon Support, NEJM Vertebroplasty Articles Spark Slowdown, Reimbursement Review
Orthopedics Settlement: Puts the Issue to Bed--Or Does It?
Orthopedics Settlement: Puts the Issue to Bed--Or Does It?
Globus Prepared for Trek with $110m from Clarus-led Group
Globus Prepared for Trek with $110m from Clarus-led Group
K2M Inc.

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel